SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DanZ who wrote (458)3/31/1999 11:51:00 AM
From: Mike M   of 5582
 
Dan-

As always you did a great job on the recap of GUMM's statement. Revenues, as I expected, were not dramatic. I look forward with anticipation to seeing revenue rise much more so in the first quarter. Zicam's impact on the market will be seasonal but should have a very positive impact and show significant growth over the next several years.

I too believe that we have survived the "earnings" announcement and can look forward to better times.

Perhaps equally significant but unheralded was the securing of financing. The $6M when available will allow GUMM to invest for greater growth. I am particularly delighted that it did not necessarily result in dilution to shareholders.

Regards,

Mike
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News